Navigation Links
Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
Date:9/3/2008

September is National Vascular Disease Awareness Month

CHARLOTTESVILLE, Va., Sept. 3 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of unmet medical needs, announced today that it has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC). The trial, designated NCT00725881 on the clinicaltrials.gov Website, is investigating TSC as a treatment for peripheral arterial disease (PAD) patients who experience the severe leg pain known as intermittent claudication. According to the PAD Coalition, approximately 8 million Americans suffer from the disease. Results from the trial are expected to be announced in early 2010.

This double-blinded, placebo-controlled trial will randomize up to 48 patients at five research sites in the U.S. Primary clinical endpoints of the study are peak walking time and claudication onset time, as demonstrated by exercise treadmill tests. Both endpoints are well-accepted by the medical community and regulatory authorities as reliable indicators of efficacy in intermittent claudication clinical trials. Safety and pharmacokinetic assessments are also being conducted during the trial.

"In addition to advancing a much-needed treatment for peripheral arterial disease patients, this Phase I/II study will also help demonstrate TSC's potential to treat other diseases related to cellular oxygen deprivation," says David G. Kalergis, JD/MBA, Chief Executive Officer of Diffusion Pharmaceuticals. "Such proof-of-concept in humans is a critical step in the advancement of our novel pharmaceutical and will support our plans to apply it to treatments for a broad range of unmet medical needs affecting millions of patients annually."

TSC is the company's lead candidate in a family of first-in-class compounds, representing a new approach to the treatment of conditions characterized b
'/>"/>

SOURCE Diffusion Pharmaceuticals LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
4. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
5. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
6. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
9. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
10. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
11. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... DIEGO , Nov. 24, 2014  GlySens Incorporated ... two million dollar grant from the National Institute of ... of the National Institutes of Health (NIH).  The grant ... GlySens second generation ICGM™ long term implantable glucose monitoring ... underway, and enrollment is expected to begin before the ...
(Date:11/23/2014)... HAYWARD, Calif. , Nov. 23, 2014 ... today that Paul F. Truex , President and ... the 2014 Annual Piper Jaffray Healthcare Conference. ... rd , at the Palace Hotel in ... Anthera Pharmaceuticals Anthera Pharmaceuticals is a biopharmaceutical ...
(Date:11/22/2014)... de 2014  BioClinica®, Inc., un proveedor líder ... eClinical, ha indicado un aumento de la demanda ... seguimiento basado en el riesgo en los ensayos ... seguimiento basado en el riesgo más allá de ... o cambio de los métodos de seguimiento. Se ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
... PLC ), a company focused on innovative cardiac ... the three,and twelve month periods ended December 31, 2007., ... with,$1,747,000 in the fourth quarter of 2006. The net ... $0.03 per diluted share, compared to net,income of $36,000, ...
... XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer ... ... March 4 Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announced ... Medicines Agency (EMEA) for,XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of,patients ...
Cached Medicine Technology:PLC Systems Reports Fourth Quarter 2007 Results 2PLC Systems Reports Fourth Quarter 2007 Results 3PLC Systems Reports Fourth Quarter 2007 Results 4PLC Systems Reports Fourth Quarter 2007 Results 5PLC Systems Reports Fourth Quarter 2007 Results 6Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 2Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 3Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 4
(Date:11/24/2014)... 24, 2014 Mental health issues ... They break up families, ruin careers, and generally ... for those that suffer,” says Hardy Nutritionals® ... showing that our specialized nutritional treatments can reverse ... on “Mind Over Matter”, the premiere episode of ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Dr. Michael ... Fertility Center, recently appeared on NBC to discuss egg freezing ... freezing has been trending in the news recently, with new ... procedure for women. , “[The companies] see it ... are on a career hot path.” Says Dr. Kettel. , ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 The ... Market 2006 to 2020 - Asia-Pacific” provides quantitative ... devices market segments: minimally invasive body contouring devices, ... The analysis includes market size data by revenue ... the following countries: China, Japan, South Korea, Australia ...
(Date:11/23/2014)... (HealthDay News) -- The holidays can be a challenge ... can trigger major meltdowns, an expert says. "Holidays ... circumstances, but when you have children with special needs, ... therapy professor at University of the Sciences in Philadelphia, ... to let your hosts or visitors know what special ...
(Date:11/23/2014)... York, NY (PRWEB) November 23, 2014 ... the past month in a federal litigation involving Byetta ... similar diabetes medications, Bernstein Liebhard LLP reports. , ... 566 claims over a class of Type 2 diabetes ... filed in the U.S. District Court, Southern District of ...
Breaking Medicine News(10 mins):Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4
... PHILADELPHIA, Dec. 24 Congressman Chaka Fattah (D-PA) releases the ... reform legislation: , "Senate Democrats deserve our thanks and ... to do, but I am confident that the House and ... the new year we will be sending President Obama a ...
... Today, The U.S. Conference of Mayors (USCM) congratulates the U.S. Senate ... millions of the uninsured. In a historic Christmas Eve session, ... Protection and Affordable Care Act. , "Not since 1963, has ... It is appropriate the most important piece of health ...
... cells generate embryonic-like cells, study finds , THURSDAY, Dec. 24 ... fight the common cold and heal wounds, but the antioxidant ... generate embryonic-like stem cells, new research suggests. , The ... Stem Cell , add to previous research that showed how ...
... , WASHINGTON, Dec. 24 "The Senate,s historic vote ... creation of a transformational national long-term services and supports insurance ... people with disabilities. The Senate bill also includes means by ... acute and long-term problems. It will stimulate innovation in ...
... , , WASHINGTON, Dec. ... critical that this step be accomplished as we continue our journey ... committed to working with Congress to ensure health insurance reform is ... Delgado, President and CEO of the National Alliance for Hispanic Health, ...
... of the Bipartisan Policy Center Report Continue to Encourage Joint ... U.S. Senate Majority Leaders Howard Baker, Tom Daschle and Bob ... and Leaders, Project on the State of American Health Care, ... and Affordable Care Act of 2009 today. , ...
Cached Medicine News:Health News:Senate Action Part of Long Road to Health Care Reform 2Health News:Former Senate Majority Leaders Baker, Daschle and Dole Commend Senate Passage of Health Care Bill 2Health News:Former Senate Majority Leaders Baker, Daschle and Dole Commend Senate Passage of Health Care Bill 3
Inquire...
Inquire...
Inquire...
... a range of 18 Ophthalmic frames ... and producted to the very hightest ... super lightweight Titanium and Beta Titanium ... host of beautifully formed and innovative ...
Medicine Products: